Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 12, 2020, Albireo Pharma, Inc. ("Albireo") held its 2020 Annual Meeting
of Stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders:
(1) elected each of Michael Gutch, Ph.D. and Roger A. Jeffs, Ph.D. to Albireo's
Board of Directors as a Class I director for a term of three years to serve
until the 2023 annual meeting of stockholders and until his successor is elected
and qualified or until his earlier death, resignation or removal ("Election of
Directors"); (2) ratified the appointment of Ernst & Young LLP as Albireo's
independent registered public accounting firm for the fiscal year ending
December 31, 2020 ("Auditor Ratification"); and (3) approved, on an advisory
basis, the compensation of Albireo's named executive officers as disclosed in
the proxy statement for the meeting ("Advisory Vote on Executive Compensation").
A more complete description of each of these matters is set forth in Albireo's
definitive proxy statement filed with the Securities and Exchange Commission on
April 17, 2020.
The number of votes cast in favor or against or withheld by the stockholders
and, where applicable, the number of abstentions and the number of broker
nonvotes on each of the foregoing matters are set forth below.
1. Election of Directors
Shares Shares Voted
Voted to Withhold Broker
Nominee For Authority Nonvotes
Michael Gutch, Ph.D. 9,032,754 121,318 1,521,835
Roger A. Jeffs, Ph.D. 9,045,184 108,888 1,521,835
2. Auditor Ratification
Shares Shares Voted Shares Broker
Voted For Against Abstaining Nonvotes
10,575,494 20,942 79,471 -
3. Advisory Vote on Executive Compensation
Shares Shares Voted Shares Broker
Voted For Against Abstaining Nonvotes
8,889,343 165,549 99,180 1,521,835
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses